Company Overview and News

10
Booze business looks at a new golden goose for profits: pot

2018-10-15 japantimes.co.jp
NEW YORK – The world’s major alcohol producers can no longer ignore the pot phenomenon, as young consumers may increasingly swap beer and cocktails for joints and cannabis-infused drinks.
STZ.B ACB WEED ACBFF STZ CGC RI

 
Vijay Rekhi: In high spirits

2018-09-28 livemint
Vijay Rekhi has fond memories of, among other things, the vehicles he has owned. Starting from a bicycle when he was 11 years old to buying a Vespa scooter as an 18-year-old and then getting his first car, they mark some sort of milestones in his life.
532432 UBL UNITDSPR UQNTY UBHOLDINGS RI 507458 UNBWY 532478

19
A Warning On Canadian Pot Stocks

2018-09-11 seekingalpha - 5
Stocks of Canadian cannabis producers and sellers are on a wild run in 2018. A selection of talked about names have doubled or tripled in value the past few months, with others not far behind. Price action like that is bound to pique the interest of investors and traders who may be wondering what has caused the surge in prices, something that is looked at in the first part of this article. Other investors and traders already familiar with the space may be questioning the valuation of major names, which is a second major focus of this article.
STZ.B PHOT ACBFF RI CANN TLRY FSPM TPX.B APH WEED DGE CCAN DGE DEO KBIO BUD NGBL CRON CBGI STZ CGC MDBX ACB HGEN HEIO AHBIF CNTTF APHQF

 
Corby Spirit And Wine: Wiser's Whisky Makes For Tasty Dividends

2018-09-05 seekingalpha
Corby has extremely steady margins in a slow-growth industry that is resilient in every economic environment.
CRBBF RI CBYDF

24
13 Reasons Why I Am Buying CV Sciences

2018-09-04 seekingalpha - 13
The past week and a half has been torturous for CV Sciences (OTCQB:CVSI) shareholders. The stock has crashed from an intraday high of $9.20 per share Monday August 20 to as low as $2.76 last Wednesday. More than a 60% haircut in less than seven trading days.
CVSI STZ.B BUD WEED AHBIF PRRDF STZ CGC RI DEO

 
Pernod Ricard SA (PDRDF) CEO Alexandre Ricard on Q4 2018 Results - Earnings Call Transcript

2018-08-31 seekingalpha
Pernod Ricard SA (OTCPK:PDRDF) Q4 2018 Results Earnings Conference Call August 29, 2018 3:00 AM ET
SCGLF SCGLY GLE MS RI

 
Our/Vodka Becomes the First Spirit Brand to Have a Global and Local Identity

2018-08-30 accesswire
Our/Los Angeles is Now Available in Retail Stores Across Southern California Including BevMo, Cost Plus, Total Wine, Bristol Farms & More
RI

4
PRESS DIGEST - Canada - Aug 29

2018-08-29 reuters - 1
Aug 29 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
PMGYF BUD HEIO AHBIF DGE RI DGE DEO PMT

 
European shares edge up, optimism from US-Mexico deal fizzles

2018-08-29 malaymail
LONDON, Aug 29 — European shares rose slightly at the open today as optimism triggered by the US/Mexico deal gradually fizzled and uncertainty grew about a similar agreement with Canada and a lasting solution to the trade spat with China.
MS RI

 
Europe Markets: European shares tick higher, but U.K. stocks dip

2018-08-29 marketwatch
European markets inched higher on Wednesday, tracking recent gains in U.S. markets that came on an apparent easing of trade-related tensions.
POFCF MS PFC POFCY RI

 
European shares edge up, optimism from U.S./Mexico deal fizzles

2018-08-29 reuters
LONDON (Reuters) - European shares rose slightly at the open on Wednesday as optimism triggered by the U.S./Mexico deal gradually fizzled and uncertainty grew about a similar agreement with Canada and a lasting solution to the trade spat with China.
MS RI

 
Brancott Estate named official wine sponsor for Emirates Team New Zealand

2018-08-27 nzherald.co.nz
Blenheim-based Brancott Estate has been named the official wine sponsor for Emirates Team New Zealand in the next America's Cup in 2021.
RI

2
U.S. stocks hit records, Peso rises on Nafta deal

2018-08-27 theedgemarkets
(Aug 27): U.S. stocks added to all-time highs, and Mexico’s peso rallied versus the dollar as the Trump administration closed in on a Nafta trade deal. Treasuries fell.
CICHY DG CICHF RI CCB 0939

2
Asian stocks set for gains; yuan holds rise on PBOC

2018-08-26 theedgemarkets
SYDNEY (Aug 27): Asian stocks were set for modest gains after the Federal Reserve reaffirmed a slow and gradual pace of policy tightening, helping push U.S. equities to a fresh all-time high. The yuan held its advance triggered by a move from China’s central bank to give it more control over its exchange rate.
CICHY DG LNSTY CICHF RI CCB 0939

 
#UnfairCommercialPractice? UK investigates celebrities over social media promotions

2018-08-16 malaymail
LONDON, Aug 16 — Celebrities and influencers who endorse products without labelling their social media posts as paid-for by brands were warned today that they were breaking the rules as Britain’s regulator launched an investigation into the trend.
RI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...